JPRN-UMIN000006014已完成2 期
Multicenter and Open-label Phase IIa Study of SI-657 in Patients with Enthesopathy (Lateral Epicondylitis, Patellar Tendinitis, Achilles Tendinitis and Plantar Fasciitis) - Multicenter and Open-label Phase IIa Study of SI-657 in Patients with Enthesopathy (Lateral Epicondylitis, Patellar Tendinitis, Achilles Tendinitis and Plantar Fasciitis)
SEIKAGAKU CORPORATIO0 个研究点目标入组 60 人开始时间: 2011年7月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who received localized injection at the involved site or any steroid topical treatment within 2 weeks before administration. 2.Exclusion criteria for each disease are below. - Lateral Epicondylitis: Patients with more severe pain due to complications within the affected upper limb than lateral epicondylitis. - Patellar Tendinitis: Patients with more severe pain due to complications within the affected lower leg than patellar tendinitis. - Achilles Tendinitis, Plantar Fasciitis: Patients with acute symptoms (i.e., sprain, injury or surgery) at the affected foot. 3.Patients with rheumatic joint diseases. 4.Patients with infectious risk at administration due to their skin disease or infection. 5.Patients, the investigator (or the subinvestigator) considers, inappropriate for entry into the trial.
研究者
相似试验
进行中（未招募）
1 期
Phase II study of PM60184 in patients with advanced colon-rectal cancer after standard treatment.Advanced Colorectal CancerMedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000257-39-ESPharma Mar, S.A.60
进行中（未招募）
不适用
A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Ageno medical, conditionhealthy, at risk volunteers will be recruited for a clinical trial to receive three vaccinations against meningococcal strain B and one vaccination against meningococcal strains A,C, W and Y.EUCTR2007-001563-29-DEovartis Vaccines and Diagnostics S.r.l.250
进行中（未招募）
不适用
A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Age - NDPrevention Meningitis/Sepsi caused by Meningococcus type B or A, C, W-135, YMedDRA version: 9.1Level: SOCClassification code 10021881Term: Infections and infestationsEUCTR2007-001563-29-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.250
进行中（未招募）
1 期
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)EUCTR2021-001530-19-HUKartos Therapeutics, Inc.56
进行中（未招募）
1 期
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)MedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001530-19-ESKartos Therapeutics, Inc.56